Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) 是一种具有生物活性的维生素 B9 叶酸衍生物,是氨基酸,核酸和脂质的一个碳原子的供体。Tetrahydrofolic acid 用作游离甲醛的受体,产生 5,10-亚甲基四氢叶酸-四氢叶酸。
生物活性 | Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups foramino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid[1]. |
IC50& Target[1] | Human Endogenous Metabolite |
|
体外研究 (In Vitro) | Tetrahydrofolic acid (0-200 μM; 3 days; Adh5-/-DT40 cells) exposure is cytotoxic to Adh5- and Fanconi anemia (FA)-deficient cells due to the accumulation of extensive DNA damage and chromosome breaks[1]. Tetrahydrofolic acid (0-100 μM; 16 hours; Adh5-/-DT40 cells) treatment strongly promots FANCD2 and ser139-H2AX focus formation in Adh5-/-cells in a dose-dependent manner[1]. Tetrahydrofolic acid exposure activates the DNA damage response (DDR) due to uncontrolled activity of the thymidylate synthase enzyme, which causes a depletion of essential nucleotides, and promotes repair by a homologous recombination mechanism[1].
Cell Viability Assay[1] Cell Line: | Adh5-/-DT40 cells | Concentration: | 0-200 μM | Incubation Time: | 3 days | Result: | Viability of Adh5-/-DT40 cells rapidly dropped. |
Western Blot Analysis[1] Cell Line: | Adh5-/-DT40 cells | Concentration: | 0-200 μM | Incubation Time: | 16 hours | Result: | Strongly promoted FANCD2 and ser139-H2AX focus formation in Adh5-/-cells in a dose-dependent manner. |
|
体内研究 (In Vivo) | Tetrahydrofolic acid (62.5 mg/kg; intraperitoneal injection; daily; Adh5-/-mice) treatment perturbs the hematopoiesis of hematopoietic cells, increases ser139-H2AX phosphorylation, and decreases the survival of progenitor cells (HSPCs) suggesting that excess Tetrahydrofolic acid could be mutagenic and genotoxic to bone marrow cells[1].
Animal Model: | Adh5-/-mice[1] | Dosage: | 62.5 mg/kg | Administration: | Intraperitoneal injection; daily | Result: | Perturbed hematopoiesis, increased ser139-H2AX phosphorylation, and decreased the survival of progenitor cells (HSPCs). |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, protect from light, stored under nitrogen *该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
溶解性数据 | In Vitro: DMSO : 20.83 mg/mL(46.76 mM;Need ultrasonic) 配制储备液 1 mM | 2.2450 mL | 11.2251 mL | 22.4502 mL | 5 mM | 0.4490 mL | 2.2450 mL | 4.4900 mL | 10 mM | 0.2245 mL | 1.1225 mL | 2.2450 mL |
*请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.67 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.67 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|